We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+0.73%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$24.1B
AUM Growth
+$1.97B
Cap. Flow
+$2.05B
Cap. Flow %
8.49%
Top 10 Hldgs %
10.49%
Holding
3,709
New
1,118
Increased
953
Reduced
622
Closed
747

Sector Composition

Rank Sector Weight
1 Healthcare 20.28%
2 Financials 16.56%
3 Technology 13.74%
4 Consumer Discretionary 11.01%
5 Communication Services 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AEON icon
801
AEON Biopharma
AEON
$11.1M
$6.37M 0.03%
9,068
+4,888
+117% +$3.41M
TU icon
802
Telus
TU
$16B
$6.36M 0.03%
289,427
-1,501,958
-84% -$33.9M
IBB icon
803
CALL
iShares Biotechnology ETF
IBB
$9.31B
$6.36M 0.03%
39,300
+27,500
+233% +$4.63M
QDEL icon
804
QuidelOrtho
QDEL
$1.09B
$6.36M 0.03%
45,025
+28,223
+168% +$3.79M
IHG icon
805
InterContinental Hotels
IHG
$23B
$6.32M 0.03%
+98,251
New +$6.35M
DAL icon
806
Delta Air Lines
DAL
$55.9B
$6.31M 0.03%
148,130
+33,906
+30% +$1.38M
MRVL icon
807
Marvell Technology
MRVL
$174B
$6.31M 0.03%
104,667
-18,348
-15% -$1.1M
CRC icon
808
California Resources
CRC
$4.75B
$6.31M 0.03%
153,854
+64,311
+72% +$2.1M
OCA
809
DELISTED
Omnichannel Acquisition Corp.
OCA
$6.3M 0.03%
636,113
+21,025
+3% +$207K
ESPR
810
DELISTED
Esperion Therapeutics
ESPR
$6.27M 0.03%
520,095
-651,975
-56% -$9.49M
DNZ
811
DELISTED
D and Z Media Acquisition Corp.
DNZ
$6.25M 0.03%
642,511
+29,800
+5% +$289K
FAAS
812
DELISTED
DigiAsia
FAAS
$6.25M 0.03%
+624,752
New +$6.15M
TMAC
813
DELISTED
The Music Acquisition Corporation
TMAC
$6.23M 0.03%
640,628
+1,108
+0.2% +$10.7K
GLNG icon
814
Golar LNG
GLNG
$4.95B
$6.17M 0.03%
475,993
+58,978
+14% +$681K
LUXA
815
DELISTED
Lux Health Tech Acquisition Corp. Class A Common Stock
LUXA
$6.17M 0.03%
+628,947
New +$6.19M
CNM icon
816
Core & Main
CNM
$8.17B
$6.17M 0.03%
+235,190
New +$6.26M
CLBTW
817
CALL
DELISTED
Cellebrite DI Ltd. Warrants
CLBTW
$6.15M 0.03%
+663,802
New +$1.53M
EBS icon
818
Emergent Biosolutions
EBS
$375M
$6.14M 0.03%
122,719
+11,296
+10% +$684K
CLAA
819
DELISTED
Colonnade Acquisition Corp. II
CLAA
$6.14M 0.03%
627,745
+1,025
+0.2% +$10K
BSKY
820
DELISTED
Big Sky Growth Partners, Inc. Class A Common Stock
BSKY
$6.13M 0.03%
+626,377
New +$6.11M
GS icon
821
CALL
Goldman Sachs
GS
$313B
$6.12M 0.03%
+16,200
New +$6.33M
XLV icon
822
State Street Health Care Select Sector SPDR ETF
XLV
$42B
$6.12M 0.03%
48,036
-31,060
-39% -$4.11M
CACC icon
823
Credit Acceptance
CACC
$6B
$6.11M 0.03%
10,438
+8,353
+401% +$4.55M
ZT
824
DELISTED
Zimmer Energy Transition Acquisition Corp. Class A Common Stock
ZT
$6.1M 0.03%
+627,264
New +$6.08M
MQ icon
825
Marqeta
MQ
$1.8B
$6.09M 0.03%
68,870
+66,950
+3,487% +$7.16M

Similar funds

Marshall Wace's Q3 2021 Portfolio in Review

As of Q3 2021, Marshall Wace held 3,709 positions worth $24.1B, up 8.9% from $22.1B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

Marshall Wace deployed $2.05B of net new capital in Q3 2021, opening 1,118 new positions and adding to 953 existing holdings. Its largest new stake was SkinHealth Systems: 4,113,430 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Biogen, an estimated $210M trimmed.

  • Marshall Wace's largest Q3 2021 buy was SkinHealth Systems: 4,113,430 shares worth $107M.
  • Marshall Wace added most to Uber in Q3 2021, an estimated $127M increase.
  • Marshall Wace's biggest Q3 2021 reduction was Biogen, cutting an estimated $210M.
  • Marshall Wace fully exited Vipshop in Q3 2021, selling an estimated $58.7M.
  • Marshall Wace's ten largest holdings make up 10% of its $24.1B portfolio in Q3 2021.
  • Marshall Wace opened 1,118 new positions and closed 747 in Q3 2021.
  • Marshall Wace's portfolio value rose 8.9% quarter-over-quarter to $24.1B.

Based on Marshall Wace's 13F filing for Q3 2021, filed 15 Nov 2021.